The veteran heart failure cardiologist shares his goals as president, why he thinks his subspecialty is so dynamic these days and what he most wishes other specialists recognized about heart failure care.
Heart failure and stepdown units of the Sydell and Arnold Miller Family Heart & Vascular Institute have been testing electrocardiogram technology.
The national PI of the ROADMAP trial shares his passion for VADs, current research projects that excite him and why he made a mid-career move to Cleveland Clinic.
Our experts share eight trends and developments that excite them most in mechanical circulatory support and beyond.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Part of the paraoxynase family, PON2 is produced in the heart and appears to safeguard the organ from stressors.
The COAPT trial finds transcatheter mitral valve repair to be safe and highly effective in a setting with no good treatment options: symptomatic mitral regurgitation secondary to heart failure.
The funding will support a three-pronged initiative using machine learning and other methods to identify factors behind survival disparities to improve survival and minimize organ wastage.
These findings suggest that the RAP/PAWP ratio is a more specific marker of right heart dysfunction than RAP or any other traditional hemodynamic variable alone.
Cleveland Clinic’s ACNO of Nursing Research and Innovation led the first study to show a direct association between decision-making in clinical heart failure care, via clinical vignette scores, and CHFN status.
As the use of LVADs for destination therapy grows, a new study offers the first guidance on whether aggressive treatment for atrial arrhythmias makes a difference in this setting.